Heya Pharmaceutical Technology

Heya Pharmaceutical Technology (Heya Pharma) is a Beijing-based biotechnology company focused on developing innovative therapeutics targeting the 'Cell cycle-related and expression-elevated protein in tumor' (CREPT), also known as RPRD1B. As a subsidiary of the Hebei Hejia Pharmaceutical Technology Group, the company leverages its deep expertise in oncology and metabolic diseases to advance a pipeline of small nucleic acid drugs and monoclonal antibodies. Its lead candidate, CREPT-618, is a first-in-class small nucleic acid drug currently in Phase 1 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and rare tumors. Heya maintains a strategic research partnership with Tsinghua University to explore the role of the CREPT/CDK9 axis in cancer progression and genomic stability. The company's research has demonstrated that targeting CREPT can inhibit tumor growth and enhance sensitivity to other therapies, such as CDK9 inhibitors and immunotherapy.